Drug Profile
Teriparatide transdermal - Corium International
Alternative Names: hPTH(1-34) - Corium International; Human PTH(1-34) - Corium International; MicroCor PTH; Parathyroid hormone (1-34) - Corium International; Parathyroid hormone transdermal - Corium International; PTH (1-34) - Corium InternationalLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Corium International
- Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Parathyroid hormone receptor type 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Osteoporosis
Most Recent Events
- 24 Jul 2019 Corium International completes a phase IIa trial in Osteoporosis (In volunteers) in Australia (Transdermal) (ACTRN12615000195550)
- 17 Dec 2018 Corium International has been acquired by Gurnet point capital
- 06 Sep 2017 Teriparatide is still undergoing phase-II clinical trials in Osteoporosis (In volunteers) in Australia (Transdermal)